Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
2024年4月10日 - 6:00AM
ビジネスワイヤ(英語)
Studies highlight advancements in technology to
detect cell-free DNA and rapid turnaround time in a real-world
clinical setting
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions
company with a focus in lung disease, today announced that new data
was presented at the American Association for Cancer Research
(AACR) Annual Meeting 2024 in San Diego, California. These
presentations highlight advancements in liquid biopsy technologies
that detect cell free DNA (cfDNA) and the clinical value of rapid
turnaround time to detect actionable tumor mutations in a
real-world clinical setting.
Details on the poster presentations:
Presentation Title: Single cell and cell-free nucleic
acid analyses of liquid biopsy specimens from a blood collection
tube using a new droplet digital PCR system Abstract
Number: 3706 Session Date and Time: Monday Apr 8,
2024 1:30 PM - 5:00 PM PT Session Title: Circulating Tumor
Cells 1 Presenter: Leisa Jackson
Presentation Title: Real-world assessment of turn-around
time for actionable variant testing in NSCLC in the community
setting Abstract Number: 6474 Session Date and
Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PM PT Session
Title: Profiling Cancer with Real-World Evidence
Presenter: Gary Pestano, PhD
An independent presentation of an exploratory analysis from
the FLAURA2 clinical study, sponsored by AstraZeneca,
was also presented as a plenary session:
Presentation Title: FLAURA2: exploratory analysis
of baseline (BL) and on-treatment plasma EGFRm dynamics in patients
(pts) with EGFRm advanced NSCLC treated with first-line (1L)
osimertinib (osi) ± platinum-pemetrexed Session Date and
Time: Tuesday Apr 9, 2024 10:45 – 11:00 AM PT Session
Title: Biomarkers: Quantifying Pharmacodynamic
Modulation Presenter: Pasi Jänne, MD, PhD
The analysis evaluated the prognostic and predictive nature of
EGFR mutations (EGFRm) detected in plasma in patients with locally
advanced/metastatic EGFRm non-small cell lung cancer receiving
first-line osimertinib in combination with chemotherapy versus
osimertinib monotherapy. Biodesix supported this research by
providing the EGFRm testing using Droplet Digital™ PCR* (ddPCR™) on
plasma samples collected prior to treatment and three and six weeks
after treatment initiation. EGFRm testing is offered in a clinical
setting by Biodesix as part of the GeneStrat® ddPCR targeted
mutation test. Results suggest that baseline detection of plasma
EGFRm may identify a subgroup of patients who would derive most
benefit from the addition of platinum-pemetrexed chemotherapy to
osimertinib as first-line treatment for EGFR-mutated advanced
NSCLC.
*Droplet Digital and ddPCR are trademarks
of Bio-Rad Laboratories, Inc.
About Biodesix
Biodesix is a leading diagnostic solutions and services company
with a focus in lung disease. The Company develops diagnostic tests
addressing important clinical questions by combining multi-omics
through the power of artificial intelligence. Biodesix offers five
Medicare-covered tests for patients with lung diseases. The
blood-based Nodify Lung® Nodule Risk Assessment testing strategy,
consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates
the risk of malignancy in incidental pulmonary nodules, enabling
physicians to better triage patients to the most appropriate course
of action. The blood based IQLung™ strategy for lung cancer
patients integrates the GeneStrat® targeted ddPCR™ test, the
GeneStrat NGS® test and the VeriStrat® test to support treatment
decisions across all stages of lung cancer with results in an
average of two to three business days, expediting the time to
treatment. Biodesix collaborates with many of the world’s leading
biotechnology and pharmaceutical companies to solve complex
diagnostic challenges in lung disease. For more information, visit
biodesix.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240409147335/en/
Media: Natalie St. Denis Natalie.StDenis@biodesix.com
1-720-925-9285
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Biodesix (NASDAQ:BDSX)
過去 株価チャート
から 4 2024 まで 5 2024
Biodesix (NASDAQ:BDSX)
過去 株価チャート
から 5 2023 まで 5 2024